Orforglipron: The Next Revolution in Metabolic Disease Management

Описание: The collected sources provide a comprehensive overview of *GLP-1-based therapeutics* for metabolic diseases, focusing on their cardiorenal protection and role in weight management. The academic review details the efficacy of existing drugs like semaglutide and the development of *next-generation multi-receptor agonists* such as tirzepatide and retatrutide, highlighting their benefits in reducing cardiovascular events and chronic kidney disease progression in patients with type 2 diabetes and obesity. Complementary news reports specifically showcase the success of the investigational *oral GLP-1 drug orforglipron* (developed by Eli Lilly), noting its substantial weight loss results—up to 12.4% in non-diabetic patients—and significant improvements in heart and metabolic risk factors. Clinical trial data comparing orforglipron to oral semaglutide confirms its superior performance in lowering A1C and promoting weight loss, positioning it as a potentially transformative, convenient, and scalable **oral alternative to injectable treatments**. Overall, the texts underscore the rapid advancements and growing market potential of this class of drugs in addressing the global public health challenge of obesity and associated comorbidities.